Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363373 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL14304968 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL12000798 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL5452846 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL295573 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL23845860 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL137622 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL723342 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460643 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460354 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150969-B2 | Synthetically enveloped virus | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-11-26 | — | — | US | claimed |
| EP-4384220-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | The Johns Hopkins University (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2023244470-A1 | SURFACE CALR CHEMICAL INDUCERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023019186-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220257604-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | US | claimed |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM INST DU CERVEAU ET DE LA MOELLE EPINIERE (FR) | 2022-03-03 | — | — | US | claimed |
| EP-3934688-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | University of Virginia Patent Foundation (US) | 2022-01-12 | — | — | EP | claimed |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2021-07-20 | — | — | US | claimed |
| US-20200316146-A1 | SYNTHETICALLY ENVELOPED VIRUS | PITTSBURGH, UNIVERSITY OF - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-08 | — | — | US | claimed |
| WO-2020185675-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-09-17 | — | — | WO | claimed |
| WO-2001054654-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001047513-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDRENS HOSPITAL LOS ANGELES RESEARCH INSTITUTE (US) | 2001-07-05 | — | — | WO | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| EP-1098642-A1 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1091745-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN'S HOSPITAL OF LOS ANGELES (US) | 2001-04-18 | — | — | EP | claimed |
| EP-0996433-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-05-03 | — | — | EP | claimed |
| WO-2000006145-A1 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | JOHNS HOPKINS UNIVERSITY (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000000207-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN'S HOSPITAL OF LOS ANGELES (US) | 2000-01-06 | — | — | WO | claimed |
| US-5976781-A | DIAGNOSING MALARIA BY MIXING BLOOD WITH ENZYME INHIBITOR, DETERMINING ENZYME ACTIVITY, COMPARING TO CONTROL SAMPLE; PLASMODIUM ENZYME IS MORE SENSITIVE TO INHIBITION SO DEACTIVATION INDICATES DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-11-02 | — | — | US | claimed |
| US-5863716-A | Treatment of plasmodium | THE LELAND STANFORD JUNIOR UNIVERSITY BOARD OF TRUSTEES (US) | 1999-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12150969-B2 | Synthetically enveloped virus | PIGS, LIPG, FURIN | UGCG 121/4885KMT2A 3109/4885MEN1 1457/4885 |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | GBA1, SMN1; SMN2, GAA | UGCG 13/4885KMT2A 2710/4885MEN1 3980/4885 |
| US-20200316146-A1 | SYNTHETICALLY ENVELOPED VIRUS | PIGS, LIPG, FURIN | UGCG 121/4885KMT2A 3109/4885MEN1 1457/4885 |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | GBA1, SMN1; SMN2, GAA | UGCG 13/4885KMT2A 2710/4885MEN1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.